Hyaluronic Acid Fillers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Hyaluronic Acid Fillers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Hyaluronic Acid Fillers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Hyaluronic Acid Fillers pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Hyaluronic Acid (HA) is a glycosaminoglycan disaccharide, which exists naturally in the body. Approximately 50% of total HA is found in the skin, and it is produced by dermal fibroblasts, endothelial cells, synovial cells, adventitial cells, smooth muscle cells, and oocytes. Injections of HA are used for reducing wrinkles in the face and for soft tissue augmentation.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Hyaluronic Acid Fillers under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Hyaluronic Acid Fillers and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Hyaluronic Acid Fillers under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
1 About GlobalData
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
3.1 Hyaluronic Acid Fillers Overview
4 Products under Development
4.1 Hyaluronic Acid Fillers - Pipeline Products by Stage of Development
4.2 Hyaluronic Acid Fillers - Pipeline Products by Segment
4.3 Hyaluronic Acid Fillers - Pipeline Products by Territory
4.4 Hyaluronic Acid Fillers - Pipeline Products by Regulatory Path
4.5 Hyaluronic Acid Fillers - Pipeline Products by Estimated Approval Date
7.4 Mar 01, 2024: Evolus Announces Results from European Head-to-Head Filler Trial
7.5 Feb 27, 2024: Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
7.6 Feb 27, 2024: LG Chem to Raise 1 tln Won in Bond Sale
7.7 Feb 22, 2024: AbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel
7.8 Feb 07, 2024: Galderma Launches ‘Next’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics
7.9 Feb 05, 2024: AbbVie's Full Year 2023 Sees 6.4% Net Revenue Drop
7.1 Jan 22, 2024: Galderma Announces Regulatory Approval for Restylane SHAYPE, a new Hyaluronic Acid Injectable Designed for Augmenting the Chin Region
7.11 Jan 04, 2024: AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call
7.12 Jan 03, 2024: Medytox Announces Executive Appointments in Luvantas, Inc
7.13 Nov 01, 2023: CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler
7.14 Oct 31, 2023: SKINVIVE by JUVEDERM Now Available from Dermatologist Dr. Ellen Turner
7.15 Oct 31, 2023: LG Chem Announces 3Q Management Performance
7.16 Oct 10, 2023: Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023
7.17 Oct 04, 2023: AbbVie to Host Third-Quarter 2023 Earnings Conference Call
7.18 Sep 28, 2023: Merz Aesthetics Continues to Fuel Confidence by Expanding Belotero Balance (+) Filler Treatment Areas
7.19 Sep 19, 2023: Revance Provides Corporate Update at Investor Day
7.21 Aug 24, 2023: CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million
7.22 Aug 01, 2023: Allergan Aesthetics Announces First Ever JUVEDERM Day
7.23 Jun 26, 2023: Collplant Achieves Milestone and to Receive $10 Million From Abbvie in Accordance With Its Regenerative Dermal Filler Product Collaboration Agreement
7.24 Jun 12, 2023: Croma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China
7.25 May 15, 2023: SKINVIVE by JUVÉDERM receives U.S. FDA approval
8 Appendix
8.1 Methodology
8.2 About GlobalData
8.3 Contact Us
8.4 Disclaimer
2.1 List of Tables
Table 1: Hyaluronic Acid Fillers - Pipeline Products by Stage of Development
Table 2: Hyaluronic Acid Fillers - Pipeline Products by Segment
Table 3: Hyaluronic Acid Fillers - Pipeline Products by Territory
Table 23: Juvederm Voluma Global - Malar Augmentation - Clinical, Instrumental and Histological Evaluation of the Combined Use of Onabotulinumtoxin A and Hyaluronic Acid Fillers in Patients with Facial Paralysis
Table 60: Saypha Volume Plus Lidocaine - A Randomized, Multi-center, Evaluator-blinded, Parallel Assignment, Active Controlled Study to Evaluate the Efficacy and Safety of Princess Voluma plus and Restylane Perlane Lidocaine for Correction of Midface Volume Deficit And/Or Midface Contour Deficiency
Table 104: IPN-21-SENSE Dermal Filler - A Multicenter, Prospective, Randomized Controlled Clinical Study of IPN-21-SENSE, a Novel Hyaluronic Acid Based Gel for Volume Deficiency in the Mid-face
Table 122: LG Chem Ltd - Ongoing Clinical Trials Overview
Table 123: YVOIRE Y-Solution 360 - A Multicenter, Randomized, Rater-Blinded, No-Treatment Control Design Clinical Investigation to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 360 for Lip Augmentation
Table 124: YVOIRE Y-Solution 540 - A Randomized, Multicenter, Evaluator-blinded, Active-controlled, Parallel-group Design Investigation to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 540 Versus YVOIRE Volume Plus in Nasolabial Folds Injection
Table 129: Lumina - A Prospective, Randomized, Controlled, Multi-center Study of the Safety and Effectiveness of Lumina in the Treatment of Nasolabial Folds
Table 170: MaiLi Extreme - A Post Market Clinical Follow Up (PMCF) Study to Assess the Safety and Efficacy of MaiLi Volume and MaiLi Extreme in the Treatment of Temporal Hollowing, Mid-Face Volume Deficit, Jawline Ptosis, and Chin Retrusion
Table 177: Teoxane SA - Ongoing Clinical Trials Overview
Table 178: Teosyal RHA 1 - A Prospective, Single Blind, Single-center Study Evaluating the Histology and Intradermal Implantation of the Teosyal RHA Collection of Fillers